It’s 2 a.m. A mother calls into a nurse triage line. Her baby isn’t screaming. She’s not rattling off symptoms. She just keeps saying, “something’s wrong.” And the nurse on the other end of that phone ...

Immunology continues to be one of the hottest areas for biotech investment, and Windward Bio is joining in with $165 million in fresh capital to support a pipeline led by a drug in pivotal testing ...

The Trump administration’s crackdown on fraud, waste and abuse continues, with the Department of Justice last week launching a new effort targeting healthcare fraud. Experts think the new strike force ...

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal that gives the Italy-based brain medicines company three commercialized rare disease products and entry into the U.S.

Bayer is paying $300 million to buy Perfuse Therapeutics, a clinical-stage biotech that offers a new growth opportunity in ophthalmology as the pharmaceutical company’s top eye product weathers ...

Rosarium Health, a company enabling aging at home, has raised $6 million in seed funding and secured partnerships with several Medicaid and Medicare Advantage plans, the company shared with MedCity ...

Disagreements between providers and payers have been moving into the courtroom over the past few weeks. The California ...

Madrigal Pharmaceuticals, maker of the first FDA-approved medicine for the fatty liver disease MASH, has been exploring combinations of that small molecule with other drugs as a way to potentially ...

Two North Carolina-based health systems, Atrium Health and WakeMed Health, announced plans to merge last week. As part of the proposed deal, Atrium plans to invest $2 billion into WakeMed and create 3 ...

UCB is adding a big piece to its immunology pipeline with a multi-billion dollar deal to buy Candid Therapeutics, a clinical-stage biotech company developing therapies in a promising but competitive ...

Despite having a longer life expectancy compared to men, women in the U.S. generally have a higher prevalence of chronic conditions. Complicating matters, women’s health remains underfunded and ...

If you follow biosimilar headlines, you might think the market is in crisis. Stories highlight nine adalimumab biosimilars launching in just one year, and a similar pattern with the ustekinumab market ...